Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH)

Global Pulmonary Arterial Hypertension (PAH) Market to Reach US$9.8 Billion by 2030

The global market for Pulmonary Arterial Hypertension (PAH) estimated at US$7.1 Billion in the year 2023, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Prostacyclin & Prostacyclin Analogs Drug Class, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Endothelin Receptor Antagonists (ERAs) Drug Class segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 7.9% CAGR

The Pulmonary Arterial Hypertension (PAH) market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Pulmonary Arterial Hypertension (PAH) Market - Key Trends and Drivers Summarized

Pulmonary arterial hypertension (PAH) remains a formidable challenge in cardiology, characterized by its progressive nature and high mortality rate. This severe condition affects the pulmonary vasculature, leading to increased pulmonary artery pressure, right ventricular failure, and potentially death. PAH is marked by pulmonary vasoconstriction and progressive occlusion of the distal pulmonary arteries. The pathogenesis involves multiple factors including endothelial dysfunction, chronic inflammation, smooth muscle cell proliferation, and pulmonary vascular remodeling. The disease`s complexity is further compounded by various etiologies such as hypoxia, tobacco exposure, genetic mutations, and developmental abnormalities. These factors necessitate a multifaceted approach to management, encompassing a deep understanding of the disease`s underlying mechanisms and classifications as delineated by the European Society of Cardiology (ESC) and European Respiratory Society (ERS).

The pathology of PAH includes significant remodeling of the pulmonary arteries, characterized by thickening of the vessel walls and accumulation of abnormal cells under the endothelium. This leads to narrowed vascular beds and occluded vessels, escalating pulmonary vascular resistance and culminating in right heart failure. Genetic research has identified mutations in genes like BMPR2, CAV1, and KCNK3 as critical contributors to PAH, enhancing our understanding and highlighting potential therapeutic targets. Biomarkers such as BNP/NT-proBNP and emerging ones like survivin and TET2 provide valuable insights into disease severity, progression, and treatment response. Treatment strategies have evolved to target specific molecular pathways involved in PAH, including prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase stimulators, each addressing different aspects of the disease from vasodilation and anti-inflammatory actions to vascular remodeling.

The growth in the field of PAH treatment is driven by several key factors. Advancements in diagnostic technologies like non-invasive imaging (echocardiograms, MRI, and CT scans) facilitate earlier and more accurate diagnoses, which is crucial for effective intervention. Increased awareness and screening practices among healthcare providers and patients lead to earlier detection and treatment initiation. Personalized medicine approaches, including genetic testing and biomarkers, enable more tailored and effective treatments, enhancing patient adherence and outcomes. The integration of digital health tools such as mobile health apps and wearable devices helps patients manage their condition more effectively by monitoring health in real-time and providing data to refine treatment plans. Expanded access to treatment through improved healthcare infrastructure and policy initiatives, along with collaborations between research institutions and pharmaceutical companies, accelerates the development of new therapies. Lastly, patient advocacy and community support play vital roles in educating patients and influencing policy, thereby increasing demand for advanced treatments and better care standards. These factors collectively enhance the understanding, management, and treatment of PAH, reflecting an integrated approach that combines technological, social, and economic dimensions.

Select Competitors (Total 23 Featured) -

• Actelion Pharmaceuticals Ltd.
• Bayer AG
• Gilead Sciences, Inc.
• Lung Biotechnology PBC
• Pfizer Inc.
• United Therapeutics Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.